Insider · CIK 0002130322
Natalie Dales
Files at ODTX (Odyssey Therapeutics, Inc.). First filing -, latest -.
In brief
Natalie Dales files SEC Form 4 as officer at ODTX (Odyssey Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Natalie Dales has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | ODTX Odyssey Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +79,773 | $0.00 | $0 | 79,773 | May 11, 2026 |
Questions about Natalie Dales
Answered from the filings on this page, as of the latest one.
Is Natalie Dales buying or selling?
Natalie Dales has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Natalie Dales's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Natalie Dales has 0.
Where does Natalie Dales file Form 4?
Natalie Dales has filed Form 4 at ODTX (Odyssey Therapeutics, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.